Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 212

1.

A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology.

Miller DS, Blessing JA, Drake RD, Higgins R, McMeekin DS, Puneky LV, Krasner CN.

Gynecol Oncol. 2009 Dec;115(3):443-6. doi: 10.1016/j.ygyno.2009.09.004. Epub 2009 Oct 4.

PMID:
19804902
2.

Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group.

Miller DS, Blessing JA, Krasner CN, Mannel RS, Hanjani P, Pearl ML, Waggoner SE, Boardman CH.

J Clin Oncol. 2009 Jun 1;27(16):2686-91. doi: 10.1200/JCO.2008.19.2963. Epub 2009 Mar 30.

3.

Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group.

Lorusso D, Ferrandina G, Pignata S, Ludovisi M, Viganò R, Scalone S, Scollo P, Breda E, Pietragalla A, Scambia G.

Ann Oncol. 2010 Jan;21(1):61-6. doi: 10.1093/annonc/mdp266. Epub 2009 Jul 15.

4.

Pemetrexed (Alimta, LY231514) demonstrates clinical activity in chemonaive patients with cervical cancer in a phase II single-agent trial.

Goedhals L, van Wiyk AL, Smith BL, Fourie SJ.

Int J Gynecol Cancer. 2006 May-Jun;16(3):1172-8.

PMID:
16803502
5.

Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer.

Miller KD, Picus J, Blanke C, John W, Clark J, Shulman LN, Thornton D, Rowinsky E, Loehrer PJ Sr.

Ann Oncol. 2000 Jan;11(1):101-3.

6.

A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study.

Tait DL, Blessing JA, Hoffman JS, Moore KN, Spirtos NM, Lachance JA, Rotmensch J, Miller DS.

Gynecol Oncol. 2011 Apr;121(1):118-21. doi: 10.1016/j.ygyno.2010.11.027. Epub 2010 Dec 14.

PMID:
21159366
7.
8.

Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.

Miller DS, Blessing JA, Bodurka DC, Bonebrake AJ, Schorge JO; Gynecologic Oncology Group.

Gynecol Oncol. 2008 Jul;110(1):65-70. doi: 10.1016/j.ygyno.2008.03.009. Epub 2008 May 5.

PMID:
18455781
9.

A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer.

Miles DW, Smith IE, Coleman RE, Calvert AH, Lind MJ.

Eur J Cancer. 2001 Jul;37(11):1366-71.

PMID:
11435066
10.

Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.

Scagliotti GV, Shin DM, Kindler HL, Vasconcelles MJ, Keppler U, Manegold C, Burris H, Gatzemeier U, Blatter J, Symanowski JT, Rusthoven JJ.

J Clin Oncol. 2003 Apr 15;21(8):1556-61.

PMID:
12697881
11.

A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer.

Dittrich C, Petruzelka L, Vodvarka P, Gneist M, Janku F, Kysela T, Melemed A, Latz J, Simms L, Krejcy K.

Clin Cancer Res. 2006 Dec 1;12(23):7071-8.

12.

Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.

Sweeney CJ, Roth BJ, Kabbinavar FF, Vaughn DJ, Arning M, Curiel RE, Obasaju CK, Wang Y, Nicol SJ, Kaufman DS.

J Clin Oncol. 2006 Jul 20;24(21):3451-7.

13.

A phase II study of pemetrexed in patients with advanced hepatocellular carcinoma.

Cohn AL, Myers JW, Mamus S, Deur C, Nicol S, Hood K, Khan MM, Ilegbodu D, Asmar L.

Invest New Drugs. 2008 Aug;26(4):381-6. doi: 10.1007/s10637-008-9124-5. Epub 2008 Feb 28.

PMID:
18305899
14.

Pemetrexed in gastric cancer: clinical experience and future perspectives.

Celio L, Buzzoni R, Longarini R, Marchianò A, Bajetta E.

Semin Oncol. 2002 Dec;29(6 Suppl 18):63-8. Review.

PMID:
12571814
15.

Open-label, single-arm phase II study of pemetrexed in the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma who have had prior platinum-based chemotherapy.

Zhang Y, Zhao L, Huang P, Wu J, Wang F, Huang Y, Zhang L.

Cancer Chemother Pharmacol. 2012 Oct;70(4):611-5. Epub 2012 Aug 19.

PMID:
22903536
16.

Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.

Matulonis UA, Horowitz NS, Campos SM, Lee H, Lee J, Krasner CN, Berlin S, Roche MR, Duska LR, Pereira L, Kendall D, Penson RT.

J Clin Oncol. 2008 Dec 10;26(35):5761-6. doi: 10.1200/JCO.2008.17.0282. Epub 2008 Nov 10.

17.

Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: A Phase II study of the Gynecologic Oncology Group.

Moore DH, Blessing JA, Dunton C, Buller RE, Reid GC.

Gynecol Oncol. 1999 Dec;75(3):473-5.

PMID:
10600310
18.

A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.

Rose PG, Brunetto VL, VanLe L, Bell J, Walker JL, Lee RB.

Gynecol Oncol. 2000 Aug;78(2):212-6.

PMID:
10926805
19.

A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Modesitt SC, Sill M, Hoffman JS, Bender DP; Gynecologic Oncology Group.

Gynecol Oncol. 2008 May;109(2):182-6. doi: 10.1016/j.ygyno.2008.01.009. Epub 2008 Mar 4.

PMID:
18295319
20.

A prospective phase II study: high-dose pemetrexed as second-line chemotherapy in small-cell lung cancer.

Grønberg BH, Bremnes RM, Aasebø U, Brunsvig P, Fløtten O, Amundsen T, von Plessen C, Wang M, Sundstrøm S; Norwegian Lung Cancer Study Group.

Lung Cancer. 2009 Jan;63(1):88-93. doi: 10.1016/j.lungcan.2008.04.003. Epub 2008 Jun 6.

PMID:
18538889
Items per page

Supplemental Content

Write to the Help Desk